RNS Number: 3817 S Hutchison China Meditech Limited 08 July 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2351 S Hutchison China Meditech Limited 07 July 2020 TR-1: Standard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1450 S Hutchison China Meditech Limited 07 July 2020 Notification of Dilution of Voting Rights. London: Tuesday, July 7, 2020: Hutchison China MediTech Limited was notified that CK Hutchison Holdings Limited shareholding 1 in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par value US $0.10 each in the capital of Chi-Med.
Hutchison China MediTech #HCM is on the brink of global launches of two assets from its internally developed oncology portfolio. In 2022 we expect US launches of surufatinib (broad NET indication) two years earlier than forecast as well as savolitinib (NSCLC). Recently the FDA granted fast-track designation to fruquintinib in mCRC and we forecast global launch in 2023. In China, HCM has laid the foundations to capitalise on the slew of additional novel oncology drugs (expected by end 2021). HCM is well funded (following the recent $100m equity investment from General Atlantic, plus warrants granted for an additional $100m in 18 months) as it accelerates the global development of its unpartnered assets and expands its global commercial outreach. Beyond 2024 we expect sustainable profitability and margin expansion. Our increased valuation is $6.3bn.
I talk to John Woolfitt, Director at multi award winning broking and investment firm Atlantic Capital Markets. John looks forward to the coming month, and discusses US job numbers, Boris and Build Build Build, and the raft of UK job cuts. He then discusses 'Covid' stocks, including Novacyt #NCYT upcoming key corporate announcements for July, including Royal Dutch Shell #RDSB and Hutchison China Meditech #HCM and trading ideas from the Atlantic dealing floor. John finishes with a recap on key points and trading ideas to help traders and investors in July.
London: Monday, June 29, 2020: Hutchison China MediTech Limited announces the following blocklisting six monthly return:. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. RNS is approved by the Financial Conduct Authority to act as a Primary...
London: Friday, June 26, 2020: Hutchison China MediTech Limited will be announcing its interim results for the six months ended June 30, 2020 on Thursday, July 30, 2020 at 12:00 noon British Summer Time.. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of...
London: Thursday, June 25, 2020: Hutchison China MediTech Limited today announces that it has entered into a definitive agreement for the sale of US $100 million of shares at a price equivalent to US $25.00 per American Depositary Share via a private placement to General Atlantic, a leading global growth equity firm. This fundraise could increase to US $200...
London: Thursday, June 18, 2020: Hutchison China MediTech Limited today announces that the U.S. Food and Drug Administration has granted Fast Track Designation for the development of fruquintinib, for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based...
Hutchison China Meditech Limited (HCM.L) Announced that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited, its 50:50 joint venture with Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, has entered into an agreement with the Guangzhou government for the planned return of HBYS's remaining 34 years land-use rights on its approximately 30,000 square meters unused site at Guang Cong Road, Tong He Town, Baiyun District, Guangzhou. The agreement signed between HBYS and the Land Development Centre of Guangzhou provides that HBYS would return the Site to the government in consideration for cash compensation of up to US$95 million. #HCM
London: Tuesday, June 9, 2020: Hutchison China MediTech Limited today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited, its 50:50 joint venture with Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, has today entered into an agreement with the Guangzhou government for the planned return of HBYS's...
Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review. London: Thursday, June 4, 2020: Hutchison China MediTech Limited today announces that the Independent Data Monitoring Committee of the FRUTIGA study of fruquintinib has completed a planned interim...
Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA. London: Monday June 1, 2020: Hutchison China MediTech Limited today announces that it has held its pre-New Drug Application meeting with the U.S. Food and Drug Administration for surufatinib for the treatment of patients with advanced neuroendocrine tumors.
RNS Number: 3686 O Hutchison China Meditech Limited 29 May 2020 Press Release. -Ongoing surufatinib study in U.S. progressive NET patients demonstrated promising efficacy irrespective of prior lines of therapy-. London: Friday, May 29, 2020: Hutchison China MediTech Limited today showcases new and updated analyses on the ongoing studies of savolitinib and...
RNS Number: 3401 O Hutchison China Meditech Limited 29 May 2020 Press Release. Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations. London: Friday, May 29, 2020: Hutchison China MediTech Limited today announced that the New Drug Application for savolitinib for the...
Hutchison China Meditech Limited (HCM.L) Announced that it has entered into a clinical collaboration agreement to evaluate the safety, tolerability and efficacy of combining two of Chi-Med's drug candidates, surufatinib and fruquintinib, with BeiGene's anti-PD-1 antibody tislelizumab, for the treatment of various solid tumor cancers, in the U.S., Europe, China and Australia. #HCM
RNS Number: 9073 N Hutchison China Meditech Limited 26 May 2020 Press Release. -Initial development focused on multi-cohort trials in the U.S., Europe, China and Australia-. LONDON, UK; CAMBRIDGE, Mass. and BEIJING, China: May 26, 2020: Hutchison China MediTech Limited and BeiGene, Ltd. today announced that they have entered into a clinical collaboration agreement to...
Hutchison China Meditech Limited #HCM Announced that new and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming ASCO20 Virtual Scientific Program, taking place on May 29-31, 2020. Chi-Med plans to hold a conference call on the following Monday, June 1, to discuss the results.
RNS Number: 8858 M Hutchison China Meditech Limited 14 May 2020 Press Release. Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program. London: Thursday, May 14, 2020: Hutchison China MediTech Limited today announces that new and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib...
RNS Number: 5443 M Hutchison China Meditech Limited 11 May 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    66.66M

Company Profile

Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapeutics and immunotherapies in oncology and autoimmune diseases.

Classification

Market Indices-
Watchlist